Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Karyotyping01:17

Karyotyping

60.6K
Overview
60.6K
Meiosis I01:49

Meiosis I

193.6K
Meiosis is a carefully orchestrated set of cell divisions, the goal of which—in humans—is to produce haploid sperm or eggs, each containing half the number of chromosomes present in somatic cells elsewhere in the body. Meiosis I is the first such division, and involves several key steps, among them: condensation of replicated chromosomes in diploid cells; the pairing of homologous chromosomes and their exchange of information; and finally, the separation of homologous chromosomes by...
193.6K
Disorders of Leukocytes01:27

Disorders of Leukocytes

956
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
956
Nondisjunction01:29

Nondisjunction

75.6K
During meiosis, chromosomes occasionally separate improperly. This occurs due to failure of homologous chromosome separation during meiosis I or failed sister chromatid separation during meiosis II. In some species, notably plants, nondisjunction can result in an organism with an entire additional set of chromosomes, which is called polyploidy. In humans, nondisjunction can occur during male or female gametogenesis and the resulting gametes possess one too many or one too few chromosomes.
75.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

332
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
332

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

The Clinicopathologic and Genomic Features of Mature Versus Blastic Plasmacytoid Dendritic Cell Neoplasms Arising From Chronic Myeloid Neoplasms.

The American journal of surgical pathology·2026
Same author

Hypomethylating agents plus venetoclax <i>versus</i> intensive chemotherapy prior to transplant in high-risk acute myeloid leukemia.

Haematologica·2026
Same author

Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.

Blood neoplasia·2026
Same author

Cardiovascular Adverse Events Associated With Bispecific T-Cell Engager Therapy.

JACC. CardioOncology·2026
Same journal

Mechanisms of resistance to macrophage checkpoint inhibitors in B-cell non-Hodgkin lymphoma for the British Journal of Haematology.

British journal of haematology·2026
Same journal

Advanced fibrosis, TP53 variants and acute/pure erythroid leukaemia: Diagnostic harbingers of ERCC6L2-related bone marrow failure syndrome?

British journal of haematology·2026
Same journal

When macrophages have more than one thing to show.

British journal of haematology·2026
Same journal

Splenic radiotherapy before allogeneic transplantation for myelofibrosis.

British journal of haematology·2026
Same journal

Real-world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T-cell therapy.

British journal of haematology·2026
Same journal

Prognostic impact of germline and somatic variants in lymphoma-associated haemophagocytic lymphohistiocytosis.

British journal of haematology·2026
See all related articles

Related Experiment Video

Updated: Jul 6, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

101

Tri-ing to decipher trisomy AML.

Shai Shimony1,2, Evan C Chen1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

British Journal of Haematology
|January 8, 2024
PubMed
Summary
This summary is machine-generated.

This study investigated trisomy acute myeloid leukemia (AML) by comparing patients with trisomy to those with normal karyotypes. Understanding trisomy AML

Keywords:
cytogenetic abnormalitiesmyeloid neoplasmstrisomy AML

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K
Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

81.4K

Related Experiment Videos

Last Updated: Jul 6, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

101
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K
Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

81.4K

Area of Science:

  • Hematology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
  • Trisomy, an increase in chromosome number, is observed in some AML cases.
  • The distinct molecular and prognostic features of trisomy AML require further elucidation.

Purpose of the Study:

  • To compare trisomy AML patients (single, double, or tetrasomy) with cytogenetically normal AML.
  • To identify distinguishing molecular and prognostic features specific to trisomy AML.
  • To contribute to a better understanding of the heterogeneity within trisomy AML subtypes.

Main Methods:

  • Comparative analysis of trisomy AML and cytogenetically normal AML patient cohorts.
  • Investigation of distinct karyotypic and mutational landscapes.
  • Evaluation of prognostic factors in trisomy AML.

Main Results:

  • Trisomy AML exhibits a unique karyotypic and mutational landscape compared to normal AML.
  • Specific genetic alterations and chromosomal abnormalities characterize trisomy AML subtypes.
  • The heterogeneity of trisomy subtypes presents challenges in comprehensive analysis.

Conclusions:

  • Trisomy AML represents a distinct entity within acute myeloid leukemia.
  • Further research into specific trisomy subtypes is crucial for targeted therapies.
  • Understanding the molecular heterogeneity is key to improving prognostic assessments in trisomy AML.